AR096848A1 - Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) - Google Patents
Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)Info
- Publication number
- AR096848A1 AR096848A1 ARP140102528A ARP140102528A AR096848A1 AR 096848 A1 AR096848 A1 AR 096848A1 AR P140102528 A ARP140102528 A AR P140102528A AR P140102528 A ARP140102528 A AR P140102528A AR 096848 A1 AR096848 A1 AR 096848A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- independently
- hydrogen atom
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proporciona un compuesto que tiene una acción antagonista del receptor de la hormona concentradora de melanina y que es útil como agente para la profilaxis o el tratamiento de la obesidad y similares. Reivindicación 1: Un compuesto representado por la fórmula (1), caracterizado porque el anillo Ar es un anillo aromático además sustituido en forma opcional; L¹ es O, S(O)ₘ₁, NR³A o CR³BR³C; L² es O, S(O)ₘ₂, NR⁴A o CR⁴BR⁴C; (con la exclusión de la combinación en que L¹ sea distinto de CR³BR³C y L² sea distinto de CR⁴BR⁴C); m1 y m2 son cada uno en forma independiente un número entero de 0 a 2; R³A y R⁴A son cada uno en forma independiente un átomo de hidrógeno o un grupo hidrocarburo sustituido en forma opcional; R³B, R³C, R⁴B y R⁴C son cada uno en forma independiente un átomo de hidrógeno o un sustituyente; cuando L¹ es CR³BR³C y el anillo Ar tiene sustituyente(s), R³B y el sustituyente se encuentran unidos en forma opcional entre sí para formar un anillo sustituido en forma opcional; X¹, X² y X³ son cada uno en forma independiente CR⁵ o N; R⁵ es un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; R¹ es un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; R² es un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; Y¹, Y² e Y³ son cada uno en forma independiente CR⁶ o N; y R⁶ es un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; o una sal del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013143940 | 2013-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096848A1 true AR096848A1 (es) | 2016-02-03 |
Family
ID=51220851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102528A AR096848A1 (es) | 2013-07-09 | 2014-07-08 | Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) |
Country Status (9)
Country | Link |
---|---|
US (1) | US9199963B2 (es) |
EP (1) | EP3019487A1 (es) |
JP (1) | JP2016523809A (es) |
CN (1) | CN105358544A (es) |
AR (1) | AR096848A1 (es) |
CA (1) | CA2917490A1 (es) |
TW (1) | TW201536767A (es) |
UY (1) | UY35650A (es) |
WO (1) | WO2015005489A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6129850B2 (ja) * | 2012-01-12 | 2017-05-17 | 武田薬品工業株式会社 | Mch受容体拮抗剤としてのベンゾイミダゾール誘導体 |
US9440987B2 (en) * | 2012-05-10 | 2016-09-13 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
PE20221327A1 (es) | 2019-12-20 | 2022-09-09 | Bayer Ag | Carboxamidas de tiofeno, acidos carboxilicos de tiofeno sustituidos y derivados de estos |
HUP2200222A1 (hu) | 2022-06-17 | 2023-12-28 | Richter Gedeon Nyrt | MCHR1 antagonisták a Prader-Willi szindróma kezelésére |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849708A (en) | 1995-06-06 | 1998-12-15 | Joslin Diabetes Center, Inc. | Promotion of eating behavior |
CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
EP0848060A3 (en) | 1996-12-11 | 2000-02-02 | Smithkline Beecham Corporation | Novel human 11CB splice variant |
CA2995542A1 (en) | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
JP2001525178A (ja) | 1997-12-03 | 2001-12-11 | スミスクライン ビーチャム コーポレーション | ヒト11cbスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法 |
WO2000049170A1 (en) | 1999-02-18 | 2000-08-24 | Smithkline Beecham Corporation | MURINE 11cby RECEPTOR |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
AU2001252596A1 (en) | 2000-04-28 | 2001-11-12 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonists |
AU2001269531A1 (en) | 2000-07-17 | 2002-01-30 | Takeda Chemical Industries Ltd. | Sulfone derivatives, process for their production and use thereof |
KR20040058191A (ko) | 2001-10-01 | 2004-07-03 | 다이쇼 세이야꾸 가부시끼가이샤 | Mch 수용체 안타고니스트 |
US7101845B2 (en) | 2002-01-31 | 2006-09-05 | Joslin Diabetes Center, Inc. | Methods of modulating β cell function |
OA12771A (en) | 2002-02-14 | 2006-07-04 | Pharmacia Corp | Substituted pyridinones as modulators of P38 map kinase. |
WO2004028453A2 (en) | 2002-09-25 | 2004-04-08 | Neurogen Corporation | Methods for preventing and treating obesity in patients with mc4 receptor mutations |
KR20050062645A (ko) | 2002-11-01 | 2005-06-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 신경병증의 예방 또는 치료제 |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
EP1564213A4 (en) | 2002-11-22 | 2009-05-27 | Takeda Pharmaceutical | IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF |
WO2004106276A1 (ja) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | 縮合環化合物 |
NL1026826C2 (nl) | 2003-08-13 | 2007-01-04 | Pharmacia Corp | Gesubstitueerde pyridinonen. |
US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
WO2005040824A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24) |
JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
EP1867341A4 (en) | 2005-03-29 | 2009-07-29 | Banyu Pharma Co Ltd | THERAPEUTIC AGENT FOR NON-ALCOHOLIC HEPATIC ADPATIVE DISEASE, AND METHOD FOR SELECTING MEDICAMENTAL CANDIDATE COMPOUND FOR THE TREATMENT OR PREVENTION OF NON ALCOHOLIC HEPATIC ADAPTIVE DISEASE |
JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2007013694A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | フェノキシアルカン酸化合物 |
EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
RU2008108984A (ru) | 2005-08-10 | 2009-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Терапевтический агент от диабета |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
CA2621470A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
TWI354668B (en) | 2006-06-27 | 2011-12-21 | Takeda Pharmaceutical | Fused cyclic compounds |
EP2077267A4 (en) | 2006-10-18 | 2010-04-07 | Takeda Pharmaceutical | FUSED HETEROCYCLIC COMPOUND |
BRPI0717722A2 (pt) | 2006-10-19 | 2013-10-29 | Takeda Pharmaceutical | Composto ou um sal do mesmo, pró-droga, ativador de glicoquinase, agente farmacêutico, métodos para ativar uma glicoquinase em um mamífero e para a profilaxia ou o tratamento de diabetes ou obesidade em um mamífero, e, uso do composto ou uma pró-droga do mesmo |
WO2008070599A1 (en) | 2006-12-05 | 2008-06-12 | Chung-Ming Sun | Indazole compounds |
US8268868B2 (en) * | 2007-01-10 | 2012-09-18 | Albany Molecular Research, Inc. | 5-pyridinone substituted indazoles |
EP2125826A1 (en) | 2007-01-10 | 2009-12-02 | Albany Molecular Research, Inc. | 5-furopyridinone substituted indazoles |
EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
BRPI0807014A2 (pt) | 2007-02-09 | 2014-04-22 | Takeda Pharmaceutical | Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto. |
US8318746B2 (en) | 2007-04-27 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Nitrogen-containing five-membered heterocyclic compound |
US20110301155A1 (en) | 2007-06-19 | 2011-12-08 | Tsuneo Yasuma | Indazole compounds for activating glucokinase |
WO2011127643A1 (en) | 2010-04-12 | 2011-10-20 | Merck Sharp & Dohme Corp. | Pyridone derivatives |
EP2558094A4 (en) | 2010-04-12 | 2013-09-25 | Merck Sharp & Dohme | PYRIDONE DERIVATIVES |
JP6129850B2 (ja) | 2012-01-12 | 2017-05-17 | 武田薬品工業株式会社 | Mch受容体拮抗剤としてのベンゾイミダゾール誘導体 |
-
2014
- 2014-07-08 AR ARP140102528A patent/AR096848A1/es unknown
- 2014-07-08 US US14/325,564 patent/US9199963B2/en not_active Expired - Fee Related
- 2014-07-08 EP EP14742376.8A patent/EP3019487A1/en not_active Withdrawn
- 2014-07-08 WO PCT/JP2014/068651 patent/WO2015005489A1/en active Application Filing
- 2014-07-08 JP JP2016500830A patent/JP2016523809A/ja active Pending
- 2014-07-08 CA CA2917490A patent/CA2917490A1/en not_active Abandoned
- 2014-07-08 CN CN201480039259.5A patent/CN105358544A/zh active Pending
- 2014-07-08 UY UY35650A patent/UY35650A/es not_active Application Discontinuation
- 2014-07-08 TW TW103123436A patent/TW201536767A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20150018373A1 (en) | 2015-01-15 |
EP3019487A1 (en) | 2016-05-18 |
JP2016523809A (ja) | 2016-08-12 |
TW201536767A (zh) | 2015-10-01 |
CA2917490A1 (en) | 2015-01-15 |
CN105358544A (zh) | 2016-02-24 |
WO2015005489A1 (en) | 2015-01-15 |
UY35650A (es) | 2015-02-27 |
US9199963B2 (en) | 2015-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118312A2 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
GT201700146A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
AR110038A1 (es) | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos | |
CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
AR102977A1 (es) | Inhibidores de erk | |
MX362582B (es) | Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR089527A1 (es) | Inhibidores de bromodominios | |
PE20171511A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
AR111983A1 (es) | ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a | |
AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
AR090836A1 (es) | Derivados de benzamida | |
AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
AR096848A1 (es) | Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
AR097963A1 (es) | Antagonistas de receptor ep3 de prostaglandina | |
EA201591645A1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре | |
AR097932A1 (es) | Antagonista del receptor de somatostatina del subtipo 5 (sstr5) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |